Anavex Life Sciences Corp. (NASDAQ: AVXL) is a Healthcare company (Biotechnology) with a market capitalization of $69M. The Maz Rating grades it against the other companies in its sector.
Anavex Life Sciences Corp.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $0.74, Anavex Life Sciences Corp. trades at 0.6x book value, with an EV/EBITDA of 4.7. It runs a gross margin of 0.0%, an operating margin of 0.0% and a net margin of 0.0%. It shows return on equity of -11.4%, return on invested capital of -15.4% and a free cash flow yield of -49.8%. On the balance sheet: a debt-to-equity ratio of 0.00 and a current ratio of 15.62. Over the past 52 weeks the share price ranged from $0.71 to $5.36, with a beta of 1.25.
Anavex Life Sciences Corp. does not currently pay a dividend.
13 Wall Street analyst ratings cover the stock: 11 Buy and 2 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.